CAR-T Therapy in China: 2026 Guide
Quick answer: as of late 2026 the NMPA has approved nine CAR-T therapies in China — eight for blood cancers and one, satri-cel, for a solid tumour. Drug prices are roughly RMB 0.99–1.29 million (≈ $139,000–182,000) against US list prices near $460,000–595,000 for the product alone. It remains a later-line option: it can produce long remissions, but it is not a cure, and many who ask do not qualify.
How many CAR-T products has China approved?
Nine approved products — the most outside the United States. Eight are for blood cancers:
- Axicabtagene ciloleucel (奕凯达, Fosun Kite): China's first, approved in 2021 for relapsed large B-cell lymphoma after two or more lines.
- Relmacabtagene autoleucel (倍诺达, JW Therapeutics): CD19-directed, and China's widest label — large B-cell, follicular and mantle cell lymphoma.
- Equecabtagene autoleucel (福可苏, IASO Bio), zevorcabtagene autoleucel (赛恺泽, CARsgen) and ciltacabtagene autoleucel (Carvykti, Legend Biotech): BCMA-directed, for myeloma after three lines.
- Three more CD19 products: 源瑞达 (Juventas), 恒凯莱 (Hengrunda Sheng), 普利得凯 (Chongqing Precision Biotech).
The ninth is the one patients ask about. Satri-cel (恺力美, CARsgen), approved on 22 June 2026, treats Claudin18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma after at least two prior lines. It is the first CAR-T approved anywhere for a solid tumour — a real milestone, and a narrow one.
What CAR-T costs in China versus the US
| Product | China (ref.) | US (ref.) |
|---|---|---|
| Axicabtagene ciloleucel (奕凯达) | ≈ RMB 1.20 million (≈ $169,000) | ≈ $503,600 |
| Relmacabtagene autoleucel (倍诺达) | ≈ RMB 1.29 million (≈ $182,000) | Not approved in the US |
| BCMA products for myeloma | ≈ RMB 1.0–1.29 million (≈ $141,000–182,000) | ≈ $528,000–555,000 |
| Satri-cel (恺力美), solid tumour | ≈ RMB 990,000 (≈ $139,000) | Not approved in the US |
| Total episode (drug plus hospital care) | 待填：具体价格 — hospital estimate per case | Commonly reported above $600,000 |
Reference values from public sources at ≈ RMB 7.1 per USD; product prices only. Not a quotation.
The drug price is not the whole bill: leukapheresis, lymphodepletion, inpatient monitoring, intensive care and follow-up are charged on top, and the hospital should give you a written estimate first. International self-pay patients cannot use Chinese public insurance or the local schemes that reimburse residents.
Who is eligible — and who is not
The treating hospital decides, not a broker or a price list. Three filters apply:
- The label. Your diagnosis must match an approved indication — large B-cell lymphoma after two lines, myeloma after three, or Claudin18.2-positive, HER2-negative gastric cancer after two. Satri-cel also needs a fresh tumour sample tested for Claudin18.2, so bring your pathology slides.
- Fitness. Most centres want ECOG 0–1, adequate heart, lung, liver, kidney and marrow function, no uncontrolled infection, no active central-nervous-system or graft-versus-host disease.
- Time. Cells take two to four weeks to manufacture, and disease that progresses in that window can end the plan after apheresis.
CAR-T is not first-line treatment, and outside Claudin18.2-positive gastric cancer it is not approved for solid tumours, where a clinical trial is usually the only route.
The realistic timeline
- Week 0. Send pathology, imaging, treatment history and biomarkers; the hospital confirms whether a product matches your case.
- Weeks 1–3. Pre-screening in Chengdu, consent and payment; apply for the visa in parallel.
- Apheresis. One day of collection, then two to four weeks of manufacturing, sometimes with bridging therapy.
- Infusion. Three to five days of lymphodepletion, then the infusion.
- Monitoring. One to two weeks inpatient, longer if fever, low blood pressure or neurological symptoms appear; intensive care is possible.
- Follow-up. Scans around day 30 and day 90; most centres ask you to stay about four weeks after infusion.
An uncomplicated course means roughly 8–12 weeks in China; complications add weeks. You cannot simply arrive and be infused — the hospital must accept the case and book an apheresis slot.
The honest limitations
CAR-T has produced durable remissions in people who had run out of options, and it has failed many of them. In large B-cell lymphoma, roughly 40% of treated patients remain in remission at five years; the rest relapse or die of the disease. In myeloma, responses are deep but nearly everyone eventually progresses. Satri-cel's benefit in gastric cancer is a progression-free survival gain measured in months, not a remission — real progress, and still far from a cure.
Serious side effects are common: cytokine release syndrome with fever, falling blood pressure and low oxygen in most patients, severe in a minority; neurological toxicity; prolonged low blood counts; infections; low immunoglobulins. Some patients never reach infusion because manufacturing fails or their condition worsens. Fees go to the hospital and are not refunded if the disease progresses. We promise no outcomes.
Entry rules and how TFUCare helps
China's visa-free and transit arrangements cover business, tourism, family visits, exchange programmes and transit. Medical treatment is not a listed purpose, so a treatment-led trip needs an M visa, normally supported by the hospital's invitation letter. Chengdu's teaching hospitals run CAR-T programmes, but commercial products are given at a limited number of designated centres, so we confirm availability before you book flights.
TFUCare translates your records, coordinates appointments with the hospital's international department, meets you at the airport, interprets at consent and follow-up visits, helps with accommodation nearby, and sends you home with an English discharge summary. Medical fees are paid directly to the hospital, never through us. Start with a free case review.
Questions we get about this
How many CAR-T therapies has China approved?
Nine as of late 2026 — eight for blood cancers and one for a solid tumour, which is the largest number of approved products outside the United States. The drug itself costs roughly RMB 1.0–1.29 million (about $139,000–182,000) in China against $462,000–593,000 in the US, and the world's first approved CAR-T for a solid tumour, satri-cel, is Chinese. But the drug is not the whole bill: hospital care, ICU time, apheresis and management of cytokine release syndrome are additional and are quoted per case, which is why we cannot publish an all-in figure.
How long does it take to get an answer?
About 24 hours on business days from the free case review. That first reply names one hospital we would point you to, gives a realistic cost range drawn from published figures, and says whether China is a sensible option for your condition at all. If the hospital has to review imaging before it will commit, expect two to four working days instead — we tell you which of the two it will be before you send anything, so you are never waiting without knowing why. Cases that need a named specialist's opinion rather than a department's take weeks, not days, and we say so rather than let the clock run.
What do you charge, and who do I pay?
The case review is free and carries no obligation. Two paid levels follow it, with the amounts published on our pricing page: a Hospital Acceptance Check, which puts your case in front of hospitals and brings back their written answer, and Full Journey Management, which covers preparation, appointments, visa invitation letter, airport pickup, bilingual accompaniment and follow-up. Medical fees are always paid by you directly to the hospital — we never handle treatment funds, and no invoice of ours ever contains a hospital charge. That separation is deliberate: it is the strongest protection against the deposit scams this industry is known for.
Can I enter China visa-free for treatment?
Not on the ordinary visa-free route, and this is the correction most websites get wrong. The officially listed permitted purposes are business, tourism, family visits, exchange and transit — medical treatment is not among them, and border inspection may refuse entry where the stated purpose does not match the visa-free rules. A trip whose main purpose is treatment therefore needs an M visa, normally supported by an invitation letter from the treating hospital, which we help prepare. Short consultations, check-ups and imaging can legitimately sit inside an ordinary visit, and we will tell you honestly which side of the line your case falls on.
Does anyone speak English at the hospital?
Inside the international department, yes — the coordinators and many of the physicians are bilingual, and some trained in the US, UK or Germany. Outside it, English is limited, and that boundary is where problems start: the pharmacy, the billing window, the imaging reception and the ward nurses may have no English at all. That is precisely why a coordinator accompanies you through registration, consultation, imaging, admission and discharge rather than leaving you to manage alone, and why we translate your records into Chinese before you arrive rather than during the appointment.